Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

NIH Genome Sequencing Program Targets the Genomic Bases of Common, Rare Disease

2/5/2016

0 Comments

 
Bethesda, MD ― The National Institutes of Health (NIH) will fund a set of genome sequencing and analysis centers whose research will focus on understanding the genomic bases of common and rare human diseases.
 
The National Human Genome Research Institute (NHGRI), part of NIH, today launched the Centers for Common Disease Genomics (CCDG), which will use genome sequencing to explore the genomic contributions to common diseases such as heart disease, diabetes, stroke and autism.
 
NHGRI also announced the next phase of a complementary program, the Centers for Mendelian Genomics (CMG), which will continue investigating the genomic underpinnings of rare, typically inherited diseases, such as cystic fibrosis and muscular dystrophy.
​“Advances in DNA sequencing are creating tremendous new opportunities for exploring how the genome plays a role in human disease,” said NHGRI Director Eric Green, M.D., Ph.D.  “Our continued focus on both rare and common diseases promises to reveal important aspects about the genomic architecture of a wide range of human disorders.”
 
CCDG researchers plan to examine a select group of disorders in order to develop approaches for using genome sequencing to study common disease more broadly.  By sequencing an expected 150,000 to 200,000 genomes of individuals with these diseases, the CCDG program aims to improve understanding of how genomic differences among people influence disease risk and to develop models for future studies of common disease.  
 
CMG scientists will build on an international network of research collaborations and sequence the genomes of individuals with a wide range of rare disorders seen around the world.  
 
Together, the CCDG and CMG programs aim to discover the genes and genomic variants – spelling differences in DNA – that cause or contribute to disease, which may eventually lead to improved diagnosis and potential treatments.
 
Pending the availability of funds, NHGRI will fund the CCDG and CMG programs for roughly $240 million and $40 million, respectively, over four years.  NHGRI will also fund a new Coordinating Center for approximately $4 million over four years to facilitate research collaborations among the program grantees, and to contribute to data analysis and program outreach.
 
In addition, the National Heart, Lung, and Blood Institute (NHLBI) will contribute to both the CCDG and CMG programs, while the National Eye Institute (NEI) will provide support to the CMG program. Both institutes are also part of NIH.
 
The new CCDG program represents an important step in the evolution of NHGRI’s long-standing, flagship Genome Sequencing Program (GSP). In its earliest phase, the GSP represented NIH’s major contribution to the Human Genome Project.
 
As DNA sequencing costs dropped, the GSP focused much of its efforts on large-scale genome sequencing projects, most recently organized as Large-Scale Genome Sequencing and Analysis Centers, one of several NHGRI genome sequencing efforts launched in 2011.
 
Those centers contributed to a wide range of pioneering genomic studies, including the 1000 Genomes Project, which involved sequencing thousands of human genomes to help chronicle genomic differences among and between populations across the world, and The Cancer Genome Atlas (TCGA), an NHGRI partnership with the National Cancer Institute that catalogued genomic changes involved in cancer.
 
Centers for Common Disease Genomics
 
Common diseases, such as hypertension, diabetes and mental illness, affect hundreds of millions of people worldwide. The causes of these diseases can be difficult to decipher because they result from a complex combination of genomic influences and environmental factors.
 
CCDG investigators will initially focus on cardiovascular/metabolic and neuropsychiatric diseases, and are considering exploring other disorders, including inflammatory/autoimmune and bone/skeletal diseases, and Alzheimer’s disease.
 
While each common disease represents a serious health burden in this country, each is also different in many ways – from the age of onset to the underlying biological changes.
 
For each disease, CCDG researchers will sequence tens of thousands of genomes from individuals with and without the disease. NHGRI will eventually select additional diseases that the centers will study.
 
“The center investigators plan to use genome sequencing to identify as many of the genes and genomic variants underlying common diseases as possible,” said Adam Felsenfeld, Ph.D., director of the NHGRI Genome Sequencing Program.
 
“Building on existing research, they will continue to uncover new biological insights into the development of common disease,” Felsenfeld said.  “At the same time, these studies will reveal genomic variants that may increase the risk for – or in some cases, protect against – diseases, which eventually might be helpful for their clinical management.”
 
Pending available funds, NHGRI will provide roughly $240 million over four years to four centers. NHLBI will provide an additional $20 million.
 
To read the complete NIH press release, click here.
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507